Big Pharma Giant Kicks Off Q1 Earnings By Boasting “Strategic Price Increases Across All Franchises” Fueled Expectations Beat

Last week, Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the first quarter of 2023. After brand name drug companies hiked prices on nearly 600 prescription drugs to start the year, Big Pharma continues to surpass earnings expectations while growing sales and posting massive profits. Johnson & Johnson reported Q1 earnings and revenue that beat Wall Street analysts’ forecasts, prompting the pharmaceutical giant to raise its full-year sales and earnings outlook.

Johnson & Johnson’s better-than-expected earnings come as the company has continued to hike prices on the prescription drugs in their portfolio.

Stay tuned as we continue to monitor earnings calls from Big Pharma for Q1 of 2023 over the next few weeks.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.